The combination antibody therapy that has been shown to reverse islet immune cell infiltration and diabetic hyperglycaemia in the IDDM rat model of human T1DM is a combination of anti-TCR/CD3 with anti-TNF-α [24]. This evidence concerns the gene TNF and type 1 diabetes mellitus.